INTRODUCTION
The size range that allows nanoparticle-based drug delivery vehicles to achieve long circulation times in-vivo also allows them to passively extravasate through discontinuous endothelium, like that found in tumors. [1] This is a significant advantage in the case of chemotherapy delivery because the particles will preferentially accumulate in tumor tissue while passing through healthy tissue with continuous endothelium, such as sensitive heart tissue. [2] [3] [4] However, one of the main challenges is that discontinuous endothelium is not limited only to the tumor tissue. Other healthy tissue also allows for extravasation and can locally accumulate circulating particles to toxic levels. Such healthy tissues include the creases of the skin on the hands and feet where it is thought that constant motion causes natural microdamage to the blood vessels allowing nanoparticles to extravasate [5] causing dose-limiting side effects. [6] Particles in this size range can also be actively taken up by healthy cells in the reticulo-endothelial system (RES). [7] Polyethylene glycol (PEG) surface coatings can delay accumulation, especially in the RES, but over time the particles still accumulate in healthy tissue including the liver. [8] There is no particle size range that will allow for long circulation times while avoiding extravasation and accumulation in these healthy tissues. [9, 10] In this work we address the issue of unavoidable accumulation in healthy tissue by designing a nanoparticle (NP) drug delivery vehicle that is comprised entirely of a light-activatable prodrug. This prodrug shows significantly reduced toxicity compared to the pure drug but can be activated to its therapeutic form by light exposure. The ability to control or tune the toxicity of the drug delivery nanoparticles through light exposure after they have been injected into the body could allow for two spatially separate populations of nanoparticles to be created. The first would be the nanoparticles that unintentionally accumulate in healthy tissue including the liver, which would not be exposed to light and thus would remain in the low toxicity state. The second would be the particles that accumulate in the target tumor tissue which can then be preferentially triggered to a highly toxic state by light exposure (Fig. 1) .
The prodrug used to make the nanoparticles was developed using the chemotherapy drug doxorubicin (DOX). It consisted of a photocleavable linker [11] (PCB) covalently bound to DOX to create the prodrug DOX-PCB. This rendered the DOX less toxic to tissue with the unique ability to restore full therapeutic function when photo-triggered. [12] The photoactivation mechanism has been fully described and the release of intact doxorubicin confirmed by HPLC/ mass spectrometry and 1 H NMR analysis. [12] Active DOX was shown to be released in-vivo from free DOX-PCB prodrug molecules inside tumors when the activating light was delivered to the center of the tumor using a fiber optic coupled light-emitting diode setup. [13] The choice of the prodrug trigger that restores the prodrug to its therapeutic form is critical to assure tumor specificity. The use of light is distinct from traditional activation mechanisms that rely on the biochemistry of the tumor. These biochemical triggers include differences in the microenvironment between the tumor and the normal tissue such as tumorassociated hypoxia or low pH [14, 15] , as well as enzymatic cleavage by enzymes which the tumor over-expresses. [16] [17] [18] The main challenge is that these biochemical triggers are often present in both tumor and non-tumor tissue [19, 20] , especially in the liver where there is both a high level of enzymatic activity and a high level of particle accumulation. The lightbased trigger can achieve a higher level of specificity than biochemical triggers because the activating wavelength of light can be delivered specifically to the tumor tissue using lightemitting diode (LED) and fiber optic technology. Recent developments in LED manufacturing enable elements to be made with sub-millimeter dimensions [21] which could allow them to be inserted [13] or implanted anywhere a biopsy needle, endoscope, or catheter can go.
The photocleavable linker in DOX-PCB has been shown to be resistant to metabolic degradation [12] which prevents undesired activation of the prodrug in healthy tissue regions, including the liver [12, 22] , but is activated by exposure to 365 nm light. This wavelength showed low absorption by internal tissue [23] including DNA [24] reducing the possibility of bioeffects. The 365 nm light is highly absorbed by melanin [25] which makes the delivered light the only significant source of this wavelength inside the body. This prevents external sources of 365 nm light from causing uncontrolled release within the body. Previous studies have shown that 365 nm light delivered by a fiber optic to the center of a 1 cm diameter tumor is heavily scattered by the tissue. [13] This scattering exposes the entire tumor volume to the 365 nm light at a sufficient intensity to cause activation of DOX-PCB in therapeutic amounts from the tumor center to the tumor margins. [13] The light-activatable prodrug would benefit from a nanoparticle carrier by increasing circulation time and tumor accumulation in a similar way that DOX benefits from Doxil®, an FDA-approved nanoliposomal formulation of DOX. [1, 26] The 80-120 nm size [10] and PEG surface coatings of Doxil® particles change the pharmacokinetics and biodistribution [27] of DOX in humans leading to an increase in circulation half-life from 9 h for the free DOX to 42 h with Doxil®.
[10] The Doxil® particle also leads to increased DOX concentrations within tumors [10] and reduced concentrations within heart tissue. [2] [3] [4] However, the active DOX payload of Doxil® causes skin ulcerations and irritation (Palmar-plantar erythrodysesthesia) when the particles unintentionally accumulate in the hands and feet which is a major dose-limiting side effect. [6] Doxil® will also accumulate in the bone marrow [7, 28] both via the reticulo-endothelial system [7] and by extravasation [9] due to the bone marrow's discontinuous endothelium [29] leading to dose-limiting myelosuppression. [6] This unintentional accumulation of nanoparticles in healthy tissue remains a major concern.
The major breakthrough in this new light-activatable nanoparticle design, when compared to Doxil®, is that any prodrug which accumulates in healthy tissue will remain in the low-toxicity state. Only the prodrug delivered to the tumor tissue will receive the activating light exposure converting it to toxic DOX. The light activation mechanism of our new prodrug nanoparticles can potentially create higher doses of active drug in the correct tissue location while causing minimal toxicity to healthy tissues.
METHODS AND MATERIALS Materials
Doxorubicin hydrochloride (DOX) was purchased from Qventas (Branford, CT) and Sigma (St. Louis, MO). Water soluble photocleavable biotin-NHS (PCB) was purchased from Ambergen (Watertown, MA). High pressure liquid chromatography (HPLC) grade acetonitrile was purchased from Fisher Scientific (Fairlawn, NJ). The human lung cancer cell line A549 and the PTK2 (Potorous tridactylus) kidney epithelial cell line (ATCC CCL-56) were purchased from the American Type Culture Collection (Manassas, VA). Trypsin-EDTA (ethylenediaminetetraacetic acid) used for cell culture was purchased from Mediatech, Inc. (Manassas, VA). All DMEM (Dulbecco's Modified Eagle Medium) media and the penicillin-streptomycin used as a media supplement were purchased from Gibco (Invitrogen, Grand Island, NY). Fetal bovine serum (FBS) used as a media supplement was purchased from Hyclone Laboratories Inc. (Logan, UT). Dulbecco's phosphate buffered saline (DPBS) was also purchased from Hyclone Laboratories Inc. (Logan, UT). All water was purified using the Milli-Q purification system from Millipore Corporation (Billerica, MA). XTT was purchased from Sigma (St. Louis, MO).
DOX-PCB Nanoparticle Synthesis
The DOX-PCB prodrug was synthesized using the procedure described in Ibsen et al. [12] . To form nanoparticles from the DOX-PCB prodrug, a single-step nanoprecipitation method was used. The DOX-PCB prodrug was first dissolved in acetonitrile at a concentration of 0.1 mg/ml. A 168 μl volume of this solution was aspirated into a 1 ml syringe fitted with a 30 Fig. 1 Schematic representation of the light-activatable prodrug nanoparticle concept. The nanoparticle is self-assembled from light-activatable prodrug molecules. The size of the nanoparticles would allow them to extravasate from circulation through discontinuous endothelium into tumor and healthy tissue. The fiber optic or LED light delivery system exposes just the tumor tissue region where the prodrug is activated and releases highly toxic drug molecules. Nanoparticles that remain in the healthy tissue do not get exposed to the light and remain intact in the low toxicity prodrug form gauge 1 in. needle, and then added dropwise to 2 ml of ultrapure water under vortex. The hydrophobic ends of the prodrug molecules clustered together to form particles in order to minimize contact with the water. The resulting sample was stirred gently for 48 h at room temperature while open to the atmosphere to evaporate the acetonitrile. This evaporation was performed to help ensure the stability of the nanoparticles and the biocompatibility of the sample. The sample was protected from ambient light during the stirring process.
The particles were then concentrated using a centrifugal evaporator to remove the desired amount of water. The particles did not aggregate as they were concentrated under the centrifugal force. Care was taken to ensure the evaporation rate did not result in the freezing of the water. DOX-PCB concentration was measured through light absorption using a Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA). All DOX-PCB nanoparticle solution concentrations are given in terms of DOX-PCB molecule content.
Particle Characterization
The DOX-PCB nanoparticles were characterized using several different methods. The size distribution of the particles was first evaluated by the Nanoparticle Tracking Analysis (NTA) technique using a NanoSight LM10 system (NanoSight Ltd., Amesbury, UK) at room temperature. Two samples of 300 μl volume were introduced into the viewing unit for the particles to be tracked and sized on a particleby-particle basis using the NTA technique. Size is reported as the average of the peak value of the size distribution from each sample. A video clip of the particles' Brownian motion was also acquired using the NanoSight system.
The size results acquired by NTA were confirmed using a Zetasizer Nano-ZS dynamic light scattering (DLS) system (Malvern Instruments, Worcestershire, UK) at room temperature with backscattering angle of 173°. Size measurements were obtained in triplicate along with polydispersity indices. Zeta potential measurements were also acquired in triplicate using this instrument.
The morphology of the nanoparticles was characterized using scanning electron microscopy (SEM) with a Phillips XL30 SEM system. The manufactured nanoparticle sample was diluted 10,000 times from its original concentration to allow observation of individual particles. A 2 μl volume of the diluted sample was placed on the surface of a polished silicon wafer and allowed to dry at room temperature overnight. The sample was coated with chromium and then imaged.
Particle Surface Characterization
The presence of the biotin-terminated PEG tail on the surface of the nanoparticles was investigated using a binding assay with streptavidin-coated Sepharose microbeads and uncoated Sepharose beads as a control. To replace the beads' 20% ethanol storage solutions with water, samples of 50 μl of Streptavidin Sepharose High Performance beads (GE Healthcare Life Sciences, Little Chalfont, UK) and uncoated Sepharose control beads (Sepharose CL-4B, GE Healthcare Life Sciences, Little Chalfont, UK) were each diluted by adding 1 ml Milli-Q water, then spun down with subsequent removal of 1 ml supernatant, followed by the addition of 50 μl fresh Milli-Q water. From these resulting bead samples, 15 μl of each bead type was added to 30 μl of unconcentrated DOX-PCB NP, and the solutions were mixed by pipette aspiration and incubated for 10 min. Brightfield and fluorescent images of the streptavidin-coated and uncoated beads with DOX-PCB NP were then taken using a Nikon E600 upright fluorescence microscope with a 20x objective.
Light-Activated Drug Release Characterization
The nanoparticle samples were evaluated for their release of pure DOX after receiving various amounts of 365 nm light exposure. Samples of 10 μl of DOX-PCB nanoparticles at 31 μM were placed into individual wells in a 96-well flat bottom assay plate (BD Biosciences, San Jose, CA) with opaque black walls and a clear bottom. The black walls helped to prevent reflections of 365 nm light inside the well and ensure uniformity of exposure between samples. The clear lid of the plate was fitted on top to help reduce the evaporation rate of the water. The samples were exposed to 2.3 mW/cm 2 of light from a Mercury Short Arc HBO bulb from OSRAM (München, Germany) with a 330-380 nm bandpass filter for increasing durations of time from 0 to 60 min. This measured light intensity took into account the absorption of 365 nm light by the lid. The samples were then collected and their volumes adjusted with water to 10 μl if any evaporation occurred.
In an in-vivo application, the DOX that was released from the nanoparticles would immediately diffuse away from the particle and associate with plasma proteins, cellular proteins, and DNA. In the specific case of this experiment the DOX-PCB nanoparticles were suspended at a high concentration in pure water which could allow the free DOX released from the particles to immediately associate with other particles. To help prevent free DOX from being sequestered into other particles, the 365 nm light exposed samples were then mixed with dimethyl sulfoxide (DMSO) in a 0.2/1 v/v ratio. The samples were then bath sonicated for 5 min. The presence of DMSO in the sample helped to keep the released DOX in solution so that it could be quantified by LC-MS/MS.
The DOX content of the samples was then quantified by LC-MS/MS using an Agilent 1260 liquid chromatography (LC) system coupled with a Thermo LCQdeca mass spectrometer (MS). The LC-MS/MS analysis used positive ion mode electrospray ionization (ESI) as the ion source with source voltage of 5 kV, capillary temperature of 250°C, auxiliary gas flow rate of 20 units, and sheath gas flow rate of 80 units. A CAPCELL MG III C-18 column (Catalog number 92744, ID 2.0 mm × length 50 mm, particle size 3 μm) was used (with guard column) for LC separation. The mobile phase A was 5% methanol in water with 0.1% formic acid. The mobile phase B was pure methanol with 0.1% formic acid. The LC gradient was increased from 30% mobile phase B to 95% mobile phase B in a duration of 10 min, then held at 95% B for 5 min, brought back to 30% B in 1 min, and then held at 30% B for 6 min. The LC flow rate was held at 0.20 ml/min. Using these LC conditions, the DOX and the two isomers of DOX-PCB were separately eluted from the LC column with a retention time of about 9.8 min for DOX, and about 13.2 and 13.7 min for the two isomers of DOX-PCB. 
Cellular Localization
The intracellular localization of the DOX-PCB nanoparticles and pure DOX was studied using the PTK2 (Potorous tridactylus) kidney epithelial cell line (ATCC CCL-56). These cells were used because they are susceptible to DOX and remain flat during mitosis, allowing for enhanced visualization of the nuclear region. This visualization capability was important since one of the main therapeutic modes of action for DOX is through DNA intercalation. The DOX-PCB nanoparticles and pure DOX are both naturally fluorescent which allowed these agents to be easily tracked through the cell. The PTK2 cells were grown in high glucose DMEM with 4.5 g/L glucose, 10% FBS, sodium pyruvate, L-Glutamine, and penicillin-streptomycin. The cells were plated in glass bottom petri dishes (MatTek Corporation, Ashland, MA) and allowed to adhere to the bottom surface.
A 1 ml media solution of DOX-PCB nanoparticles was prepared by first adding 10x DPBS to a 4.1 μM solution of DOX-PCB nanoparticles in water to achieve a 1x DPBS concentration, and then adding the resulting solution to the same DMEM media described above to achieve a final DOX-PCB content of 2 μM. This spiked media sample was then added to the PTK2 cells seeded in the glass bottom petri dishes after removing their previous growth media. A 1 ml media solution of 2 μM DOX was prepared in the same manner with the DPBS content matched to the above nanoparticle solution, and the DOX media solution was added to the cells in the same manner as described above. The cells were incubated with the spiked media samples for 2 h. Live fluorescent images of the cells were obtained using a Zeiss Axiovert 200 M Microscope (Zeiss, Thornwood, NY) using a 63x phase III, NA 1.4 oil immersion objective. All microscope control and imaging utilized the RoboLase system [32] .
To study the change in cellular localization after activation, the cells incubated with the DOX-PCB nanoparticles were exposed to the 365 nm light source for 120 s. The cells were then allowed to incubate in the 365 nm light-exposed media for 1 h. The cells were reanalyzed using the microscopy system described above. The RoboLase system allowed the same cells that where imaged before 365 nm light exposure to be relocated and imaged again after 365 nm light exposure.
Cytotoxicity
An IC 50 study was conducted to determine the toxicity of the DOX-PCB nanoparticles to cancer cells before and after 365 nm light exposure relative to free DOX using the human lung cancer cell line A549. The cells were grown on sodium pyruvate-free DMEM media containing L-glutamine, 4.5 g/L of glucose, penicillin-streptomycin and 10% FBS. The adherent cells in the expansion flask were detached using trypsin (.25% trypsin / 2.21 mM EDTA) and plated onto a 96-well plate at a density of 10 4 cells per well in 100 μL of media. The cells were incubated at 37°C overnight to allow them to adhere to the bottom of the well.
Experiments were run in two replicates under three different conditions. The first condition was incubation with pure DOX, the second was incubation with DOX-PCB nanoparticles with no 365 nm light exposure, and the third was incubation with DOX-PCB nanoparticles that had previously been exposed to 60 min of 365 nm light (2.3 mW/cm 2 ) from the same light source used in the light-activated drug release characterization study. The 365 nm light exposure itself has been shown to have no significant effect on cell viability with 60 min of exposure [12] .
The spiked media samples were prepared ahead of time using stock solutions of 200 μM DOX and 200 μM DOX-PCB nanoparticles in water. A sample of the pure DMEM media described above was concentrated to 80% of the original volume. The concentrated media was rediluted to its original volume using the stock solutions of drug to achieve solutions of DOX and DOX-PCB nanoparticles at 13.3 μM in the media. A 1/3 serial dilution was then performed to create concentrations that ranged from 13.3 μM to 2.0 nM. The 80% volume concentrated media rediluted to 100% volume with pure sterile water with no drug added was used as the control for each condition. The incubation media in each well was then replaced with the above prepared solutions causing minimal disturbance to the cells. The cells were allowed to incubate at 37°C for 72 h.
At 72 h, the In Vitro Toxicology Assay Kit (TOX2) from Sigma Aldrich was used to perform an XTT cell viability assay. Phenol red free DMEM media containing 10% FBS and penicillin-streptomycin from Gibco was used for the XTT assay to prevent phenol red interference with the absorption measurements. After 30 min of incubation time, the absorbance of each well was measured using a Tecan Infinite M200 plate reader (San Jose, CA, USA). The collected absorbance values were used to create percent viability vs. dose curves with the PRISM 4.0 program from GraphPad Software Inc. (La Jolla, CA, USA) using the sigmoidal doseresponse (variable slope) curve fit. IC 50 values were then determined from the fitted curves. The statistical analysis was performed using MATLAB R2015a software.
RESULTS AND DISCUSSION Nanoparticle Preparation and Characterization

T h e p r o d r u g c o m p o u nd , c a l l e d D o x o r u b i c i nPhotocleavable Biotin (DOX-PCB)
, was formed by blocking the free amine located on the sugar moiety of DOX with a nitrophenyl group conjugated to a short polyethylene glycol linker and terminated with a biotin (PCB) as seen in Fig. 2a . The structure of DOX-PCB has been characterized using high resolution mass spectrometry, HPLC/mass spectrometry, and absorption spectral analysis. [12] Three dimensional modeling of the molecular conformation of DOX-PCB in water using ChemDraw is shown in Fig. 2b . This hairpin shape results from the hydrophobic aglycone structure of DOX interacting with the hydrophobic nitrophenyl group. This gives the molecule a hydrophobic head and a hydrophilic tail consisting of the PEG linker and biotin (Fig. 2c) . We hypothesized that this dual hydrophobic/hydrophilic structure would allow the prodrug molecules to self-assemble into nanoparticles up on in jection in to a queous solution usin g a nanoprecipitation process.
As described in the methods section, we successfully used a single-step nanoprecipitation process to fabricate the first nanoparticles made entirely from light-activatable prodrug ( Fig. 2d and e) . The self-assembly fabrication method of DOX-PCB nanoparticles is relatively simple, giving it strong potential for future scale-up. Size results obtained using Dynamic Light Scattering (DLS) showed that the DOX-PCB nanoparticles had a unimodal size distribution with an average diameter of 102 ± 2 nm as shown in Table I . Size results obtained from Nanoparticle Tracking Analysis (NTA , Table I ) confirmed the nanoparticle size at approximately 100 nm in diameter. Zeta potential was measured at −42 ± 4 mV, which supports that the nanoparticles have sufficient repulsive interactions to be stably monodispersed in solution.
Scanning electron microscope images of the DOX-PCB nanoparticles are shown in Fig. 2e . The particles are spherical in shape with a size range that appears slightly smaller than the results obtained by DLS and NTA, which may be an effect of the nanoparticles dehydrating during the drying preparation used for SEM.
The surface coating of the nanoparticles was studied by observing their interaction with streptavidin-coated Sepharose microbeads. If the hydrophilic biotin-terminated PEG tail of the DOX-PCB molecule formed a coating on the surface of the nanoparticles, then we would expect the biotin to strongly attach to the avidin on the coated microbeads. Since the DOX-PCB nanoparticles are inherently fluorescent we could monitor this binding interaction by fluorescence imaging. In Fig. 3a , there is a strong fluorescence signal on the avidin-coated microbeads arising from the DOX-PCB nanoparticles binding to the surface. Bare Sepharose beads showed no fluorescence signal indicating that there was no nonspecific nanoparticle binding (Fig. 3b) .
The results from Figs. 2e and 3 indicate that when nanoprecipitated, the prodrug molecules form a spherical cluster comprising the core of the nanoparticle while the molecules at the surface point their hydrophilic tails into the water as shown in Fig. 2d .
The DOX-PCB nanoparticles were able to be concentrated to at least 0.22 mg/ml without aggregation. This also supports that the prodrug molecules on the outer layer of the nanoparticle oriented themselves such that the PEG chain interfaced with the water and prevented hydrophobic interactions between particles and subsequent aggregation. The particles maintained a stable size in water at 4°C for over 6 months.
These nanoparticles were formed using only the lightactivatable prodrug molecules themselves without the need for any support scaffold. This utilized the entire volume of the nanoparticle to carry prodrug thereby maximizing the payload capacity. This is different from most other nanoparticle designs that require a scaffolding or structural barrier to contain the drug payload. These structural components take up valuable volume inside the nanoparticle which reduces the amount of payload that can be loaded.
The DOX-PCB nanoparticles have a~99% loading efficiency of the prodrug as determined by high pressure liquid chromatography showing very low quantities (< 2%) of DOX-PCB left in the supernatant after the nanoparticles were removed from the synthesis solution through filtration.
Light Activation and DOX Release
Release of the active DOX from the DOX-PCB nanoparticles was studied by exposing samples of the particles to constant levels of 365 nm light for periods of time that ranged from 5 to 60 min. Significantly increasing amounts of pure DOX were released from the nanoparticles upon increasing 365 nm light exposure as shown in Fig. 4 . The amounts of released DOX at t = 0, 5, and 60 min were found to be significantly different from one another (P ≤ 0.05) in direct comparisons using a two-sample t-test (two-sided) performed at a 5% significance level. This shows clear increases in DOX quantity over time. A high rate of release was observed within the first 5 min of light exposure followed by a slower rate of release. This second release rate was observed to be linear with the 365 nm light exposure time (R 2 = .97) (Fig. 4) . This indicates that an increase in the amount of light exposure results in a greater amount of DOX release.
Cellular Localization
The localization of free DOX and the DOX-PCB nanoparticles in the PTK2 kidney epithelial cell line is shown in Fig. 5 . them to be tracked within a cell. The PTK2 cells were chosen due to their unique tendency to remain flat during mitosis improving the ability to image the nuclear DNA and determine cellular localization. One of the known modes of therapeutic action of pure DOX is by DNA intercalation, [30] and through interactions with DNA polymerase I and topoisomerase II. [31] Free DOX is seen to strongly associate with the cell nuclei as shown in panel 5b. Prior to 365 nm light exposure (Fig. 5d) , the DOX-PCB in the nanoparticles can be seen in the cell cytoplasm possibly binding to the Golgi apparatus or the endoplasmic reticulum, but not associating with the cell nuclei which remain dark. After exposure to the 365 nm light, the nuclei of the cells show increased fluorescence (Fig. 5f ) indicating that the DOX released from DOX-PCB was associating with the nucleus as therapeutically expected.
Cytotoxicity of the DOX-PCB Nanoparticles Figure 6 shows A549 human lung cancer cell cytotoxicity data under three different experimental conditions including incubation with the DOX-PCB nanoparticles before light exposure, incubation with an equal dose of free DOX, and incubation with the DOX-PCB nanoparticles after light exposure. A549 cancer cells were chosen due to their known sensitivity to DOX. Before exposure to light, the DOX-PCB nanoparticles displayed a significant reduction in toxicity and a 30-fold reduction in IC 50 concentration when compared to the same dose of free DOX (IC 50 value of 4.37 μM for DOX-PBC NP and 0.14 μM for DOX). The observed lack of interactions between the DOX-PCB prodrug and the cellular DNA shown in Fig. 5d could contribute to this reduction in toxicity.
As shown in Fig. 4 , pure DOX was released from the nanoparticles upon exposure to 60 min of 365 nm light (2.3 mW/cm 2 ). This free DOX significantly increased the toxicity of the entire sample and reduced the IC 50 value to 1.58 μM. The DNA intercalation of the released DOX shown in Fig. 5f would have contributed to the photoactivated sample's observed increase in cellular toxicity.
The number of DOX-PCB prodrug molecules that convert to pure DOX can be increased by increasing the dose of light through the use of higher power LED light sources or by increasing the exposure time as shown in Fig. 4 . The release of more DOX would increase the cellular toxicity of the DOX-PCB nanoparticle sample and would result in a further reduction of the IC 50 .
The unique light-activatable properties of the DOX-PCB nanoparticles make them promising as a means to locally control the production of pure DOX within tumor tissue while sparing healthy tissue throughout the body from toxic levels of DOX exposure. The size and surface characteristics of the DOX-PCB nanoparticles make them likely to accumulate in tumor tissue and also in specific sites of healthy tissue including the bone marrow and the hands and feet in a similar manner observed with Doxil®. However, the demonstrated reduction in toxicity of the DOX-PCB prodrug payload would make this unavoidable accumulation of the prodrug less toxic to the healthy tissue compared to an equivalent accumulation of DOX. This could result in reduced skin ulcerations in the hands and feet as well as reduced bone marrow toxicity which Along with this reduction in off-target toxicity comes the ability to therapeutically treat the tumor tissue because pure DOX would only be released from the particles that have accumulated inside the 365 nm light-exposed tumor tissue (Fig. 1) . The successful delivery of the light to tumor tissue has already been demonstrated in mouse models [13] and can be developed for human use as implantable LED systems allowing for long exposure times that can stretch into multiple hours or even days.
A unique potential of this technique is that by adjusting the intensity or delivery schedule of the 365 nm light, the DOX release rate could be tailored to make DOX bioavailable from the accumulated particles at a rate that results in the greatest tumor response.
The overall reduction in the toxicity of the DOX-PCB nanoparticles also opens up the possibility of giving a higher dose of these nanoparticles to patients than what can be achieved using Doxil®. This might result in overall higher doses of pure DOX accumulation in tumor tissue after light activation.
The water solubility of DOX-PCB was greatly improved by the nanoparticle formulation. Free DOX-PCB molecules have very low water solubility and could not be detected in water using mass spectrometry analysis. However, with the The DOX-PCB nanoparticles showed a 30-fold higher IC 50 value than the DOX control. The IC 50 of the DOX-PCB nanoparticle sample decreased after 60 min of photoactivation. Error bars show the standard deviation. **P ≤ 0.01 and *P ≤ 0.05 by a two-sample t-test (twosided) performed at the 5% significance level compared to the DOX-PCB NP value at the same time point nanoparticle formulation we were able to achieve a concentration of 200 μM DOX-PCB in water. The increased solubility is likely due to the hydrophilic surface of the nanoparticle that is formed by the hydrophilic tails of the DOX-PCB molecules located at the particle surface as demonstrated in Fig. 3 . The use of high concentrations of Captisol® cyclodextrin can also greatly enhance the water solubility of DOX-PCB molecules as has been used previously for in-vivo administration. [13] However, the new DOX-PCB nanoparticle formulation presented here has several advantages over the cyclodextrin formulation.
The cyclodextrin keeps the DOX-PCB soluble in saline only when the cyclodextrin is at high concentrations before injection but not when diluted in blood. Thus the circulation half-life and biodistribution of DOX-PCB are subject to the properties of the DOX-PCB molecule itself and not associated with the cyclodextrin carrier. Changing the circulation properties of the free DOX-PCB molecules would require chemical modifications of the DOX-PCB molecules themselves, which could have negative impacts on their desirable properties such as the hairpin conformation and light activation.
The nanoparticle formulation maintains the solubility of DOX-PCB even when diluted into cell culture media. The biodistribution and circulation half-life of DOX-PCB in the nanoparticle formulation will likely be heavily dependent on the nature of the nanoparticle as discussed in the introduction. The resulting changes to biodistribution and circulation halflife would occur without having to make any chemical changes to the DOX-PCB molecule. In the future, further changes to the biodistribution and circulation properties of the nanoparticles can be made by adding surface coatings to the nanoparticles also without changing the DOX-PCB molecular structure. The nanoparticle formulation is also less viscous than the cyclodextrin formulation which makes it easier for intravascular injection.
CONCLUSIONS
The proof-of-concept work described here demonstrates the ability to create self-assembled nanoparticles entirely from light-activated prodrug molecules. These nanoparticles have an average diameter of about 100 nm and feature a PEG coating that interfaces between the core of the particle and the surrounding water. These particles were shown to be significantly less toxic to A549 human lung cancer cells compared to pure DOX with a 30 times reduction in IC 50 . The DOX-PCB prodrug nanoparticles did not show any evidence of interaction with cellular DNA which likely contributed to the reduction in toxicity. Upon exposure to 365 nm light, pure DOX was released from the nanoparticles in significantly increasing amounts with a linear dose response. The released DOX was shown to associate with the cellular DNA significantly increasing the toxicity of the sample. The stability and size properties of the DOX-PCB nanoparticles along with the ability to release DOX when exposed to 365 nm light make these particles promising for future in-vivo studies to reduce active DOX concentrations in healthy tissues that actively and passively accumulate nanoparticles while simultaneously delivering a therapeutic dose of DOX to tumor tissue.
